[{"id":"f7adec30-958d-4721-9a82-00722f4075ec","acronym":"PULSE","url":"https://clinicaltrials.gov/study/NCT03992456","created_at":"2021-01-18T19:37:42.598Z","updated_at":"2024-07-02T16:35:02.247Z","phase":"Phase 2","brief_title":"Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer","source_id_and_acronym":"NCT03992456 - PULSE","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" EGFR • HER-2 • KRAS • BRAF • PIK3CA • MET • NRAS • MSI • PTEN • CD73 • TGFA","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 amplification • PIK3CA mutation • MET amplification • KRAS wild-type • NRAS wild-type","tags":["EGFR • HER-2 • KRAS • BRAF • PIK3CA • MET • NRAS • MSI • PTEN • CD73 • TGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 amplification • PIK3CA mutation • MET amplification • KRAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 04/24/2020","start_date":" 04/24/2020","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 10/07/2024","study_completion_date":" 10/07/2024","last_update_posted":"2024-05-21"},{"id":"2368e794-6a95-4b8e-bfab-f3ed9d06481c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01955460","created_at":"2021-01-18T08:52:28.248Z","updated_at":"2024-07-02T16:35:08.687Z","phase":"Phase 1","brief_title":"Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma","source_id_and_acronym":"NCT01955460","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" NGFR • TGFA","pipe":" | ","alterations":" TILs","tags":["NGFR • TGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 10/15/2014","start_date":" 10/15/2014","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-04-19"},{"id":"110ea52b-e84e-4c4f-ac59-5c89e4d16963","acronym":"EPITHEM","url":"https://clinicaltrials.gov/study/NCT04576429","created_at":"2021-01-18T21:50:49.552Z","updated_at":"2024-07-02T16:36:16.766Z","phase":"","brief_title":"Immune Profiles Evolution Under Immunotherapy for Melanoma","source_id_and_acronym":"NCT04576429 - EPITHEM","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" VEGFA • IFNG • IL6 • TNFA • CXCL10 • IL2 • CCL20 • IL10 • CCL19 • CCL2 • GZMB • IL17A • IL1A • IFNA1 • IL1B • IL1RN • TGFA • TNFSF10 • CXCL1 • IL33","pipe":"","alterations":" ","tags":["VEGFA • IFNG • IL6 • TNFA • CXCL10 • IL2 • CCL20 • IL10 • CCL19 • CCL2 • GZMB • IL17A • IL1A • IFNA1 • IL1B • IL1RN • TGFA • TNFSF10 • CXCL1 • IL33"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 01/27/2021","start_date":" 01/27/2021","primary_txt":" Primary completion: 01/01/2031","primary_completion_date":" 01/01/2031","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2022-02-23"},{"id":"bb6f4b6a-83b5-40d3-a692-dfad62cafb92","acronym":"PPS4B","url":"https://clinicaltrials.gov/study/NCT00399607","created_at":"2021-01-18T01:23:55.164Z","updated_at":"2024-07-02T16:37:27.175Z","phase":"","brief_title":"Calcium/Vitamin D, Biomarkers \u0026 Colon Polyp Prevention","source_id_and_acronym":"NCT00399607 - PPS4B","lead_sponsor":"Emory University","biomarkers":" MYC • BCL2 • TERT • MLH1 • MSH2 • APC • CDH1 • PTGS2 • TGFB1 • CDKN1A • TGFA • BAK1","pipe":" | ","alterations":" BAX expression","tags":["MYC • BCL2 • TERT • MLH1 • MSH2 • APC • CDH1 • PTGS2 • TGFB1 • CDKN1A • TGFA • BAK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAX expression"],"overall_status":"Completed","enrollment":" Enrollment 264","initiation":"Initiation: 06/01/2006","start_date":" 06/01/2006","primary_txt":" Primary completion: 02/01/2016","primary_completion_date":" 02/01/2016","study_txt":" Completion: 08/01/2016","study_completion_date":" 08/01/2016","last_update_posted":"2016-12-08"}]